Medicinal product name Tecentriq
Pharmaceutical form Concentrate for solution for infusion
Strength 1200 mg 
Information from the MAH on shortages No information on expected shortages
Availability of medicinal product
Product No.Package sizeWholesalers' stock state
EU/1/17/1220/001 KZSN1 Is available
Legal status Rx Prescription (Pr.II onk. ķīm. ter.)
KZS NHS Reimbursed medicines
Summary of product characteristics, package leaflet and labeling text  Summary of product characteristics, patient information leaflet and labeling text approved by the European Medicines Agency is available on European Medicines Agency website
Risk minimisation measuresIzglītojošie materiāli pacientam Izglītojošie materiāli pacientam
Vēstule veselības aprūpes speciālistam Vēstule veselības aprūpes speciālistam
Vēstule veselības aprūpes speciālistam Vēstule veselības aprūpes speciālistam
Conclusion on the therapeutic and cost effectiveness of medicines Feb 4, 2021 C34
 Oct 28, 2021 C34
 Aug 19, 2022 C34
 Sep 19, 2022 C22
 Oct 26, 2022 C34
ATC code L01FF05 Antineoplastic agents

Medicinal products (1)

Availability of medicinal product Wholesalers Package size, content Primary packaging Maximum admissible pharmacy price (€ incl. VAT) Product No. Labelling
 Is available (according to the information provided by wholesalers)
(73 containers)
Roche Latvija, Tamro, Recipe Plus N1
(1200 mg/20 ml)
Glass vial 4742.23 
KZS*
EU/1/17/1220/001  Summary of product characteristics, patient information leaflet and labeling text approved by the European Medicines Agency is available on European Medicines Agency website
* Indication about medicine on the List of state reimbursed medicines is just informative. Source of the information is the National Health Service. For details please visit the NHS website.

Registration information

Marketing authorisation No. EU/1/17/1220/001
Date of authorisation Sep 21, 2017
Marketing authorisation holder, country Roche Registration GmbH, Germany